SecBot SecBot
SECBOTREPLAY Home › Report › CRMD

CRMD · Acquires Heron assets for $250M

CorMedix Inc. · DEFA14A filed Nov 10, 2026 at 17:17 ET

At the news

NEUTRALIMPACT 6/10

DEFA14A filed Nov 10, 2026 at 17:17 ET

CorMedix announced a definitive agreement to acquire substantially all assets of Heron Therapeutics for $145M cash plus ~14.6M shares of CorMedix stock, plus earn-outs and royalties. The deal adds four commercial-stage products (ZYNRELEF, APONVIE, CINVANTI, SUSTOL) with ~$150M in trailing 12-month revenue and is expected to close in Q1 2027, subject to Heron stockholder approval and regulatory clearances. Management expects the transaction to be immediately accretive to earnings and free cash flow, with $45M-$60M in annual operating cost synergies by year-end 2027.

  • Upfront consideration: $145M cash + ~14.6M shares of CorMedix common stock (fixed at $7.20/share reference price, ~$77.6M value at $5.32/share)
  • Heron eligible for up to $55M in earn-out payments tied to ZYNRELEF 2028 net sales ($25M if >=$65M, additional $30M if >=$95M)
  • Heron eligible for 5% royalty on combined CINVANTI, SUSTOL and certain pipeline product net sales exceeding $25M in each of 2027-2029
  • Rubric Capital Management to equitize ~$38M of Heron convertible debt into CorMedix stock in 4 tranches

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access